Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
3
×
boston blog main
life sciences
national blog main
san francisco blog main
3
×
boston top stories
clinical trials
deals
kaleido biosciences
national top stories
new york blog main
akouos
astellas pharma
astellas pharmaceuticals
atlas venture
audentes therapeutics
avidity biosciences
azacitidine
beta-thalassemia
bluebird bio
california institute for biomedical research
dacogen
decibel therapeutics
decitabine
dna
duchenne muscular dystrophy
dyne therapeutics
epigenetics
epizyme
facioscapulohumeral muscular dystrophy
farydak
fda
flagship pioneering
frequency therapeutics
fulcrum therapeutics
gene therapy
harvard university
hearing loss
insulated genomic domains
What
medicines
3
×
therapeutics
3
×
developing
drug
ipo
affects
ago
aims
americans
approach
approved
based
biotech
biotechs
called
considering
data
date
debuts
diseases
drugs
dyne
early
epigenetic
epigenetics
expected
experimental
eyes
fda
field
flagship’s
frequency
genetic
having
hearing
humans
ipos
long
loss
meds
Language
unset
Current search:
medicines
×
therapeutics
×
boston
×
" san francisco blog main "
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
